All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 269 points (-1.5%) at 17,131 as of Monday, June 27, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 483 issues advancing vs. 2,516 declining with 99 unchanged.

The Health Care sector currently sits down 2.7% versus the S&P 500, which is down 1.8%. On the negative front, top decliners within the sector include

Universal Health Services

(

UHS

), down 4.9%,

Incyte

(

INCY

), down 4.2%,

Cigna

(

CI

), down 4.0%,

Agilent Technologies

(

A

), down 3.9% and

Biomarin Pharmaceutical

(

BMRN

), down 3.8%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3.

Heartware International

(

HTWR

) is one of the companies pushing the Health Care sector higher today. As of noon trading, Heartware International is up $27.62 (92.1%) to $57.60 on heavy volume. Thus far, 7.8 million shares of Heartware International exchanged hands as compared to its average daily volume of 311,700 shares. The stock has ranged in price between $57.45-$57.60 after having opened the day at $57.53 as compared to the previous trading day's close of $29.98.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

HeartWare International, Inc., a medical device company, designs, develops, manufactures, and markets miniaturized implantable heart pumps or ventricular assist devices (VAD) for the treatment of advanced heart failure in the United States, Germany, and internationally. Heartware International has a market cap of $581.5 million and is part of the health services industry. Shares are down 40.5% year-to-date as of the close of trading on Friday. Currently there are 7 analysts who rate Heartware International a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Heartware International

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally high debt management risk and generally disappointing historical performance in the stock itself. Get the full

Heartware International Ratings Report

TST Recommends

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Sanofi

(

SNY

) is up $0.61 (1.6%) to $39.06 on heavy volume. Thus far, 5.7 million shares of Sanofi exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $38.42-$39.14 after having opened the day at $38.80 as compared to the previous trading day's close of $38.45.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. Sanofi has a market cap of $107.6 billion and is part of the drugs industry. Shares are down 9.8% year-to-date as of the close of trading on Friday. Currently there are 3 analysts who rate Sanofi a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Sanofi

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income and expanding profit margins. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full

Sanofi Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Johnson & Johnson

(

JNJ

) is up $0.59 (0.5%) to $116.22 on average volume. Thus far, 4.3 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 6.9 million shares. The stock has ranged in price between $115.00-$116.44 after having opened the day at $115.00 as compared to the previous trading day's close of $115.63.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. Johnson & Johnson has a market cap of $322.9 billion and is part of the drugs industry. Shares are up 12.6% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate Johnson & Johnson a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Johnson & Johnson

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Johnson & Johnson Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).